BioCorRx to meet with the FDA for injectable, sustained-release opioid addiction therapy

BioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19.

The Anaheim, Calif.-based company said it is slated to review the development and marketing plan for BICX101, an injectable, sustained-release formulation of naltrexone as a therapy for opioid addiction and alcohol use disorders.

Get the full story at our sister site, Drug Delivery Business News.

The post BioCorRx to meet with the FDA for injectable, sustained-release opioid addiction therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2rDcR0Y